. For a number of years our laboratory has worked on the development of a new and sensitive immunochemical technique, the enzymeimmunoassay (EIA) Schuurs, 1971, 1972; van Weemen et al, 1974) . This method has also been studied by several other groups of investigators, particularly by Perlmann (1971, 1972) and . The present paper describes the application of a solid-phase enzyme-immunoassay for the detection of IHBsAg. injections of purified HBsAg in complete Freund's adjuvant at two-week intervals until a reciprocal titre of antibody to HBsAg (anti-HBs) of > 512 in a standard immunodiffusion set-up was attained with both subtype ay and ad. The resulting antiserum was tested by immunodiffusion against normal human serum (undiluted and diluted from 1:2 to 1:32). The antiserum was absorbed with insolubilized normal human serum proteins until no antibodies to human serum proteins could be detected. The gammaglobulin fraction was precipitated with 14% (w/v) Na2SO4, and the precipitate was dissolved in 0-0175 M phosphate buffer pH 7-6 and dialysed against the same buffer.
Since the discovery of the relationships between Australia antigen, now called hepatitis B surface antigen (HBsAg), and serum hepatitis (type B hepatitis) a number of immunochemical techniques with different specificity, sensitivity, and practicability for the detection of HBsAg have been described. A recent survey of these methods is given in a WHO Technical Report (World Health Organization, 1975) . For a number of years our laboratory has worked on the development of a new and sensitive immunochemical technique, the enzymeimmunoassay (EIA) Schuurs, 1971, 1972; van Weemen et al, 1974) . This method has also been studied by several other groups of investigators, particularly by Perlmann (1971, 1972) and . The present paper describes the application of a solid-phase enzyme-immunoassay for the detection of IHBsAg.
Materials and methods

HEPATITIS B SURFACE ANTIGEN
Purified HBsAg was obtained from positive donor plasmas in the way described by Schuurs and Wolters (1975) .
SHEEP ANTI-HBs GAMMAGLOBULIN Sheep were immunized by repeated intramuscular Received for publication 24 February 1976 injections of purified HBsAg in complete Freund's adjuvant at two-week intervals until a reciprocal titre of antibody to HBsAg (anti-HBs) of > 512 in a standard immunodiffusion set-up was attained with both subtype ay and ad. The resulting antiserum was tested by immunodiffusion against normal human serum (undiluted and diluted from 1:2 to 1:32). The antiserum was absorbed with insolubilized normal human serum proteins until no antibodies to human serum proteins could be detected. The gammaglobulin fraction was precipitated with 14% (w/v) Na2SO4, and the precipitate was dissolved in 0-0175 M phosphate buffer pH 7-6 and dialysed against the same buffer.
ANTIBODY-COATED MICROTITRE PLATES
The wells of Microtiter's plates (Cooke) were filled with 0-1 ml sheep anti-HBs gammaglobulin fraction having a protein concentration of 0 03 mg/ml. The liquid was removed from the plates after overnight incubation at 4°C, the plates were washed four times with 0'04 M TRIS-buffer pH 7 4, dried over silicagel, and stored at 4VC in the presence of silicagel.
ANTIBODY-ENZYME CONJUGATE Horse-radish peroxidase (Miles; RZ 3-0) was linked to sheep anti-HB8 gammaglobulin in a protein ratio of 4:1 by the 'two-step' method of Avrameas A ratio of less than 2-1 and more than 1-5 was considered to be equivocal (±).
CONFIRMATION OF PRESUMPTIVE POSITIVES
Samples found positive in the screening test described above were serially diluted in 0 9 % NaCl (undiluted to 1:32 with a dilution factor of 2) and subjected to a neutralization procedure: 100 Schuurs and Kacaki (1974) .
Subspecificities of HBsAg positive sera were determined by immunodiffusion as described by van Kooten Kok-Doorschodt et al (1972 In the final stage of the antigenaemia, some patients still reacted positively in EIA, while RIA was already negative. This was found in five patients 2Performed by Professor V. Mudrid. if ETA results were measured colorimetrically, and in three patients if eye reading was used. Six patients showed episodes of negative reactions, as shown in figure 2. Most serum samples of these patients were negative in all tests during these periods. In three cases, however (patient 13 in week 9, patient 14 in week 10, and patient 19 in week 12), the RIA was negative while the ETA was true positive. In summary, EIA was positive in eight sera (colorimetrically) and in six cases (read with the naked eye) where RTA was negative.
FRESH BLOOD DONOR SERA Of 679 fresh sera from blood donors, three were found to be weakly positive in EIA screening (eye reading). None of the three could be neutralized by specific antiserum. All 679 sera were negative by rHA.
Discussion
The preliminary results obtained with EIA show that this new test for HBsAg has a sensitivity that compares very favourably with that of RIA.
Titration of HBsAg subtype ad resulted in similar dose-response curves for both test systems, while the slope of the curve obtained with subtype ay was steeper for EIA. According to the data of the German Reference Panel, the detection level of HBsAg in ETA is at least 10-5 ng/ml for the ad subtype and 2-4 ng/ml for the ay subtype (table III) . If the HB.Ag concentration detected by at least 67% of the participating G. Wolters, L. Kuijpers, J. Kaeaki, and A. Schuurs laboratories (Gerlich et al, 1976 ) is taken as the detection level of RIA, this level is in the order of 3-4 ng/ml for subtype ad and 5-10 ng/ml for subtype ay. This indicates that, with respect to subtype ad, the sensitivity of EIA is lower than that of RIA by a factor of 2-3. On the contrary, with respect to subtype ay, the sensitivity of ElA is about three times higher provided that a ratio of > 2-1 (for both subtypes) is accepted as a positive cut-off value. In our view, this small difference in sensitivity towards the two subtypes is rather a characteristic of the immune reagents than of the test procedure. Antisera with slightly different subtype specificity profiles are now being investigated.
It might be of interest to note here that the one 'negative' sample found equivocal in ETA (table III) but negative in RIA contained anti-HBs (Thomssen, Gerlich, and Stamm, personal communication) , so that one cannot completely exclude the presence of HBsAg in immune complexes.
The results obtained with our dilution series (tables I and II and figure 1), the CLB panel ( Concerning the interesting observation of the reappearance of HBsAg positivity by EIA and/or RIA during reconvalescence in six cases (figure 2), there were no clinical or biochemical changes observable in these patients which could explain this phenomenon (Mudric and Vukovic, 1975) . Karvountzis et al (1975) described patients with two episodes of hepatitis which, however, were in no instance HBsAg-positive in both episodes. An intermittent antigenaemia in chimpanzees infected with hepatitis B virus was found by Berquist et al (1975) in the early course of the disease. We are not aware of any publication dealing with more than one HBsAg positive episode in humans during acute hepatitis B such as we found. This phenomenon may be of epidemiological interest, since the majority of patients who showed this HBsAg-negative period had already been discharged from the hospital as 'HB8Ag-negative'.
As far as the specificity of the EIA screening test is concerned we consider the incidence of three false positives found in the group of 679 fresh donor sera (<0-5 %) to be satisfactory.
The method for confirmation of presumptive positives was considered satisfactory. A series of dilutions of up to 1:32 was, in most cases, sufficient to obtain a conclusive result. All false positives were only weakly reactive in the screening. Strong presumptive positives always turned out to be true positive when tested at higher dilutions. Thus a confirmatory result of all false positives and most true positives is available on the day after screening.
We are now investigating a simpler confirmation procedure in which the predilution of sample is superfluous. The method is the same as the screening procedure except that an incubation with human anti-HBs is inserted after the binding of HBsAg from the sample to the solid phase and before the addition of conjugate. Preliminary results are encouraging. Details will be presented elsewhere.
Tests for the detection of HBsAg in donor blood should be as sensitive as possible (cf. WHO Technical report, 1975) . On the other hand, every screening test should also be as easy and practicable as possible. As is apparent from our results, ELK equals the sensitivity of RIA, thus belonging to the most sensitive test systems for HBsAg at present available.
The advantages of EIA over RIA are evident. Radio-iodinated reagents have a short shelf life and require expensive, rather sophisticated equipment for their detection. In an increasing number of countries the handling of radioactive material and the disposal of radioactive waste become subject to legal limitations.
ELA has none of these disadvantages but it does equal the sensitivity of RIA. This is already the case when the results are read by the naked eye. If a more objective reading and a somewhat higher sensitivity are desired, the use of colorimetric reading may contribute to this end. In conclusion, ETA represents an easy and modern answer to the requirement of highly sensitive HBsAg detection, especially for less well equipped laboratories.
On the basis of the data described above we are organizing a multicentre efficacy trial of the test, the results of which will be published later. 
